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1. Introduction 
Amyotrophic Lateral Sclerosis (ALS) is the most common chronic neurodegenerative 
disorder of the motor system in adults. It is a relatively rare disease with a reported 
population incidence of between 1.5 and 2.5 per 100,000 per year worldwide and a gender 
ratio of 3:2 men: women. Amyotrophic Lateral Sclerosis is characterized by the loss of motor 
neurons in the cortex, brain stem, and spinal cord, manifested by upper and lower motor 
neuron signs and symptoms affecting bulbar, limb, and respiratory muscles.  Death usually 
results from respiratory failure and follows on average two to four years after onset, but 
some may survive for a decade or more. 
Amyotrophic Lateral Sclerosis is a devastating condition with unknown aetiology and no 
current cure.  The symptoms in ALS are diverse and challenging and include weakness, 
spasticity, limitations in mobility and activities of daily living, communication deficits and 
dysphagia, and in those with bulbar involvement, respiratory compromise, fatigue and 
sleep disorders, pain and psychosocial distress. The International Classification of 
Functioning, Disability and Health (ICF) (World Health Organization, 2001), defines a 
common language for describing the impact of disease at different levels: impairment (body 
structure and function), limitation in activity and participation (see Figure 1). Within this 
framework ALS related impairments (weakness, spasticity), can limit ‘‘activity” or function 
(decreased mobility, self-care, pain) and ‘‘participation” (driving, employment, family, 
social reintegration). ‘‘Contextual factors’‘, such as environmental (extrinsic) and personal 
factors (intrinsic) interact with all the other constructs to shape the impact of ALS on 
patients and their families. The impact of ALS upon patients, their caregivers (often family 
members) and on society is substantial, often beginning long before the actual diagnosis is 
made, and increasing with increasing disability and the need for medical equipment and 
assisted care (Klein and Forshew, 1996).  
Given the broad spectrum of needs, current management spans from diagnosis (acute 
neurological needs) through to symptomatic and supportive rehabilitation and palliative 
care. The interface between neurology, rehabilitation and palliative care is of utmost 
importance to ensure co-ordinated care for persons with ALS rather than duplicating 
services (Royal College of Physicians National Council for Palliative Care and British Society 
of Rehabilitation Medicine, 2008). It should be noted however that the focus of this chapter 
is on the rehabilitation phases, hence discussion of acute neurological and palliative care 
aspects are limited.  
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Rehabilitation is defined as ‘‘a problem solving educational process aimed at reducing 
disability and increasing participation experienced by someone as a result of disease or 
injury’‘ (Wade, 1992). Although it is sometimes effective in reducing impairment, its 
principal focus is to reduce symptoms and limitations at the level of activity and 
participation, through holistic interventions, which incorporate personal and environmental 
factors. The multidisciplinary rehabilitation team (see Figure 2) comprises of a group of 
clinical professionals with expertise in ALS, directed by a physician, who work as an 
integrated unit to provide seamless care which is patient-centred, flexible and responsive to 
the evolving nature of the condition (Hardiman, 2007). The role of multidisciplinary 
rehabilitation in ALS is supported by a recent Cochrane review (Ng et al., 2009) which 
suggested some advantage for quality of life without increasing healthcare costs, reduced 
hospitalisation and improved disability with conflicting evidence for survival.  
 
 
 
 
 
 
 
 
 
 
Fig. 1. The interaction between the various domains of the International Classification of 
Functioning, Disability and Health (adapted from (World Health Organization, 2001)) 
ALS 
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Fig. 2. The multidisciplinary rehabilitation team in ALS (adapted from (Hardiman, 2007)) 
A proposed model for service interaction in caring for persons with ALS shows involvement 
of neurologists and palliative care teams in the acute and terminal phases of care, with a 
relatively smaller role for rehabilitation physicians. However rehabilitation plays a major role 
in long-term care and support (over years) in the more slowly progressive phase (Royal 
College of Physicians National Council for Palliative Care and British Society of Rehabilitation 
Medicine, 2008). Early rehabilitation intervention and treatment has much to contribute to 
improve health and quality of life prior to accumulation of disability through symptomatic 
and supportive therapies to enhance functional independence and community integration and 
reduce barriers (such as lack of knowledge about treatment, economic constraints) (Kemp, 
2005). Disability management in ALS should also be planned, with deficits should be 
anticipated (over time) to avoid ‘‘crisis management’‘. As patients deteriorate the rehabilitation 
and palliative care approaches can overlap, i.e. ‘‘neuropalliative rehabilitation”. Key skills in 
neuropalliative rehabilitation include: understanding disease progression, symptom control, 
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managing expectations, issues relating to communication, addressing end of life issues, legal 
issues (mental capacity, wills), specialist interventions (ventilation), equipment needs, 
counselling and support, and welfare advice (Royal College of Physicians National Council for 
Palliative Care and British Society of Rehabilitation Medicine, 2008).  
The literature presented in this review includes all levels of evidence for multidisciplinary 
rehabilitation of ALS (including randomised and clinical controlled trials, case studies and 
expert opinion). 
2. Rehabilitation issues in ALS 
Amyotrophic Lateral Sclerosis is a fatal disease with a challenging progressive course that 
results in a broad and ever-changing spectrum of care needs. Symptoms are varied (see 
Table 1) and need to be carefully assessed and managed. The timing of provision of 
appropriate care is important as whilst information needs to be provided when patients are 
psychologically in the right frame of mind, the options of certain interventions may be time-
limited as the disease continues to progress. 
 
Weakness 94% 
Dysphagia  90% 
Dyspnoea 85% 
Pain 73% 
Weight loss 71% 
Speech issues 71% 
Constipation 54% 
Cough 48% 
Sleep issues 29% 
Emotional lability 27% 
Drooling 25% 
Table 1. Symptoms experienced by ALS patients (adapted from (Oliver, 1996)) 
2.1 Respiratory dysfunction 
Most deaths in ALS are due to respiratory failure from respiratory muscle weakness, hence 
the diagnosis and management of respiratory symptoms is important (Figure 3) (Miller et 
al., 2009a). Counselling may be initiated at the time of diagnosis especially if respiratory 
symptoms are present and/or forced vital capacity (FVC) is <60% of predicted. Early 
symptoms may be suggestive of nocturnal hypoventilation (eg. frequent arousals, morning 
headaches, excessive daytime sleepiness, vivid dreams) rather than overt dyspnoea (Miller 
et al., 2009a). It is important to discuss the options of respiratory choices, including 
tracheostomy and ventilatory support well before these are clinically indicated to enable 
advance planning or directives. It is also important to offer patients information about the 
terminal stages of ALS and reassure regarding terminal hypercapnoeic coma and resulting 
peaceful death, as many may fear ‘‘choking to death’‘ (Borasio et al., 2001b). 
Respiratory function should be evaluated every three months from the time of diagnosis. 
Whilst FVC is the most commonly used (Melo et al., 1999) and significantly predicts survival 
(Czaplinski et al., 2006), it can be insensitive to slight changes in muscle strength (Fitting et 
al., 1999). The maximal sniff nasal inspiratory force (sniff nasal pressure) may be more 
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appropriate especially in those with bulbar weakness (no mouthpiece) and may be more 
sensitive to changes in diaphragmatic and respiratory muscle strength (Stefanutti et al., 
2000;Lyall et al., 2001). It is also more reliably recorded in the later stages of ALS (Morgan et 
al., 2005). 
Initial management can include chest physiotherapy and postural drainage, especially if the 
patient has difficulty clearing secretions from the chest (Shaw, 2003). A suction machine 
may also be helpful. Preventing respiratory infections is a primary goal and pneumococcal 
and influenza vaccines should be administered. Respiratory muscle exercise can be 
instituted and may delay the onset of ventilatory failure (Schiffman, 1996). 
Non-invasive ventilation (NIV) should be considered in respiratory dysfunction (see Figure 
3) especially for nocturnal symptomatic respiratory compromise. A recent Cochrane review 
concluded that NIV significantly improves quality of life when tolerated and may prolong 
survival in those with normal to moderately impaired bulbar function especially if used for 
 4 hours/day (Radunovic et al., 2009). Successful use of NIV is dependent on respiratory 
therapists and patients working closely and patiently through the adjustment phase of NIV, 
especially with selection and tolerance of face masks. A small dose of anxiolytic may assist 
with the process in select patients. Bulbar involvement and executive dysfunction may also 
reduce compliance (Miller et al., 2009a). 
Invasive ventilation should be offered when longer-term survival is the goal. Counselling is 
necessary with regards to benefits and burden (expense, intensive physical support with 
suctioning and nursing care, high caregiver burden) as many may not be able to manage 
invasive ventilation at home, thus requiring nursing home placement (Kaub-Wittemer et al., 
2003;Miller et al., 2009a). There is evidence however that the 10-20% of persons with ALS 
who undergo invasive ventilation (including those administered at the time of acute 
respiratory failure without advance discussion) appear to have good acceptance and 
satisfactory quality of life (Vianello et al., 2010). 
2.2 Communication 
Dysarthria is common as a result of bulbar involvement and is often a source of significant 
frustration to the persons with ALS and their families. Early changes include nasality or 
reduced vocal volume and changes in oral movement rates and speech rates (Yorkston et al., 
1993). As weakness and spasticity of the oral and laryngeal muscles increase, imprecise 
consonant production, hypernasality, harsh vocal quality, slowed rate of speech and breath 
volumes affect intelligibility (Hillel and Miller, 1989). Speech pathologists can teach the 
patient to slow speech rate, exaggerate articulation and improve respiratory efficiency 
through phrasing (Francis et al., 1999). Palatal lift and palatal augmentation prostheses may 
also be of some use to reduce the hypernasal aspect of dysarthria (Esposito et al., 2000).  
As intelligibility in ALS worsens, Augmentative and Alternative Communication (AAC) is 
required. AACs can improve quality of life by optimising function and assisting with decision 
making (Brownlee and Palovcak, 2007). AACs range from no or low technology (gestures, 
communication boards with letters) to high-tech electronic communication devices that allow 
the user to have voice output (Brownlee and Palovcak, 2007). For example, speech-generating 
devices such as LightWRITERs are commonly used. These devices can be used as long as there 
is voluntary motor movement (including eye gaze). The specific access method depends on the 
abilities of the patient – for example, pointing with a body part or pointer, adapted mice or 
joysticks or switches and scanning technology can be used. For those who have no voluntary 
www.intechopen.com
  
Amyotrophic Lateral Sclerosis 
 
562 
motor control for communication, a recent case study using a brain-computer interface system 
has been reported and appears promising (Sellers et al., 2010). The emotional aspect of using 
an alternative form of communication however can result in significant patient resistance and 
acceptance as the ability to speak and use language is what distinguishes us from all other 
species (Pinker and Jackendoff, 2005;Brownlee and Palovcak, 2007). Hence, acceptance of an 
AAC may take weeks to months. 
 
 
Fig. 3. Respiratory management algorithm in ALS (adapted from (Miller et al., 2009a)) 
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A source of significant frustration for those with speech difficulties is use of the telephone. 
Technology is available and varies from country to country. In the United States, ‘‘Speech to 
Speech” technology can be used, where trained communication assistants are used by the 
patient to complete phone calls. They are trained to use superior equipment to hear the 
caller and place the call, then repeat verbatim what the caller says so the call is completed 
successfully . 
2.3 Swallowing and nutrition 
Dysphagia affects a third of persons with ALS at onset and the majority by late disease 
(Higo et al., 2004). It increases the risk of suboptimal caloric and fluid intake and can worsen 
weakness and fatigue (Borasio, 2001). Aspiration pneumonia (13%) is a contributor to 
respiratory complications and is associated with increased mortality with mean survival 
time post-infection of 2 months (Sorenson et al., 2007). 
Difficulties in the oral preparatory stage of swallowing (preparation of food for propulsion 
to the pharynx) is common (Mayberry and Atkinson, 1986). Symptoms include jaw 
weakness, fatigue, drooling, choking on food and slow eating. In addition, loss of upper 
limb function and fear of choking or depression can further impact on self-feeding abilities 
and oral intake (Slowie et al., 1983). A speech pathologist can evaluate the degree of 
dysphagia through bed-side assessments and/or further imaging (eg videofluroscopy). Mild 
dysphagia can be managed with specific interventions such a alteration of food consistency, 
upright positioning, small bolus size, soft collar for neck extensor weakness and the chin-
tuck technique, in which the person flexes their neck to the anterior chest wall as they 
swallow, narrowing the inlet to the larynx and reducing the chance of food aspiration. 
Dieticians monitor nutritional status through body weight, percentage weight loss and body 
mass index. Common advice includes high calorie diets, texture modification and 
prescription of nutritional supplements (Rio and Cawadias, 2007). Patients may show 
nutritional compromise even before bulbar symptoms become significant (Slowie et al., 
1983) as in addition to muscle wasting, persons with ALS at all stages of disease often do not 
meet their energy requirements (Kasarskis and Neville, 1996). Dehydration is also a 
common and important problem contributing to fatigue and thickened secretions (Francis et 
al., 1999). 
As dysphagia progresses, evidence (Level B) suggests a percutaneous endoscopic 
gastrostomy (PEG) or equivalent (eg. radiologically inserted gastrostomy) is indicated to 
supplement oral intake (as long as this remains safe) for weight maintenance (Loser et al., 
2005). PEGs prolong survival but there is currently little evidence regarding the impact of 
PEG on quality of life (Langmore et al., 2006). Timing of a PEG can be challenging. 
Indicators may include weight loss (5-10% of body weight loss implies nutritional risk 
(Francis et al., 1999)) and reduced FVC. If FVC falls below 50% of predicted (Kasarskis et al., 
1999), risks of largyngeal spasm, localised infection, gastric haemorrhage, technical 
difficulties of PEG placement and respiratory arrest increase (Mazzini et al., 1995;Mathus-
Vliegen et al., 1994)). 
Sialorrhoea can be a significant issue in ALS and is generally not related to increased saliva 
production but rather to impaired ability to swallow saliva, combined with facial weakness 
causing labial incompetence and neck weakness causing the head to tip forward (Francis et 
al., 1999). Improved positioning, use of a cervical collar and orolingual exercises may be 
helpful. Medications such as anticholinergics and tricyclics can also be trialled (Schiffman 
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and Belsh, 1996), as can suction machines. In the US, most commonly used medications are 
amitriptyline, glycopyrrolate, atropine and propantheline (Forshew and Bromberg, 2003). 
However, medications may further thicken secretions, hence should be used with caution in 
those with respiratory insufficiency or poor cough. More recently, botulinum toxin injected 
into the salivary glands (parotid, submandibular) appears to be safe and has been used to 
treat sialorrhea with beneficial effects lasting approximately 3 months (Verma and Steele, 
2006;Contarino et al., 2007). Thick oropharyngeal secretions may be treated with increased 
fluid intake, humidification of air, cough augmentation, suction machines and guaifenesin 
(Forshew and Bromberg, 2003). 
2.4 Exercise 
The effects of exercise and safe therapeutic range in ALS are poorly understood. It is 
generally thought that weakness and muscle fibre degeneration may be accelerated by 
overwork or heavy exercise as it is already functioning close to its maximal limits (Johnson 
and Braddom, 1971). However, inactivity leads to deconditioning and disuse weakness. In 
addition, muscle and joint spasticity can cause pain, contractures and further loss of 
function. A recent Cochrane review (Dalbello-Haas et al., 2008) identified two trials (n = 52), 
which addressed therapeutic exercise in ALS. The trials examined the effects of moderate 
intensity, endurance type exercise on spasticity, and effects of moderate intensity resistance 
type exercises in ALS. Although one of the trials reported improvement in function and 
quality of life, both trials were too small to determine to what extent strengthening exercises 
were beneficial or harmful in this population (Dalbello-Haas et al., 2008). A more recent 
pilot study demonstrated that repetitive rhythmic exercise – supported treadmill 
ambulation training was feasible, tolerated and safe for patients with ALS and appeared to 
improve work capacity and gait functioning in patients with ALS who were dependent on 
assistive devices for ambulation (Sanjak et al., 2010). In view of the paucity of evidence to 
guide exercise prescription, the current recommendations are (Chen et al., 2008): 
 Stretching exercise to improve flexibility to maintain muscle length and joint mobility 
and prevent contractures. 
 Strengthening exercise of sub-maximal (low, non-fatiguing) intensity, with degree of 
resistance tailored to muscle strength.  
 Aerobic/endurance exercise may improve cardio-respiratory fitness and is probably 
safe but adequate oxygenation, aeration and carbohydrate load is important to reduce 
oxidative stress load. Supported treadmill ambulation training can be considered if 
available. 
2.5 Mobility and activities of daily living 
In early stages of disease, rehabilitation aims to prolong independence in mobility and 
activities of daily living, prevent complications such as falls, contractures, and 
musculoskeletal pain, maintain strength, range of movement and conditioning through an 
appropriate exercise program, educate the patient and family about the disease, provide 
psychological support, evaluate the home for safety and teach energy conservation 
techniques (Khanna et al., 2007). 
As weakness worsens, the physiotherapist can instruct the patient and family in safe transfer 
techniques (eg. between bed and chair, in and out of cars), optimise gait pattern and provide 
gait re-training with appropriate gait aids (eg. walking frame, sticks) and orthoses (ankle-foot 
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orthosis to facilitate foot clearance during gait and stabilise knee to prevent falls). Occupational 
therapists can fabricate with upper limb orthoses to assist with fine motor function. For 
example, patients with distal weakness can improve hand function with wrists braced in 30 
extension which improves efficiency of grip and addition of a universal cuff can assist those 
with weak grasp in feeding and typing (Francis et al., 1999). Other adaptive equipment is also 
provided, such as built-up cutlery for eating, Velcro fasteners for dressing, long-handled aids, 
and bathroom equipment (rails, over-the-toilet frames, bath boards, shower chairs, commodes). 
Wheelchairs are generally eventually required although introduction of a wheelchair whilst 
a patient is still ambulant, for intermittent community use, is important to enhance energy 
conservation. Future needs should be anticipated and considered when prescribing a 
powered wheelchair (eg. reclining, tilt-in-space, custom seating, and modifiable control 
system) to optimise independence and social interaction whilst preventing contractures, 
compression nerve palsies, skin breakdown and aspiration. A motorised scooter may be 
more appropriate for some patients (Francis et al., 1999). Other equipment such as hospital 
beds with pressure-relieving mattress and hoists for lifting might also be required. 
Caregiver training in the use of hoists is important to prevent injury. 
A recent study (n=44) (Ng et al., 2011) showed that a small but significant gap exists from 
the perspective of persons with ALS with regards to advice and assistance relating to 
continued employment and driving.  Healthcare providers may underestimate the 
importance of maintaining employment as a priority in a fatal condition such as ALS and 
hence under treat this issue. For these persons, the use of assistive technology may be 
particularly useful, especially in employment where computer use is crucial. Computer 
technology is fast advancing and options include different types of keyboards, mouse 
alternatives, switches, interfaces, mounting systems, integrated communication/computer 
access packages, software and systems. For those who have some proximal arm control, 
track balls, type writing sticks and forearm supports may be useful. In persons with ALS 
who have more severe upper limb weakness, head tracking systems, on-screen keyboards 
and voice recognition software may be required. Text-entry software such as Dasher (which 
is free) can be used whenever a full-size keyboard cannot be used such as on a palmtop 
computer or with a joystick, touchscreen, trackball, headpointer, or eyetracker . There are 
also many mouse alternatives available -- eyegaze system, foot control mouse, head tracking 
mouse, joysticks and switch-adapted mouse. 
Assistive technology can have a dramatic effect on restoring and maintaining independence, 
a sense of control and quality of life. Apart from technologies that assist with mobility and 
communication which have already been discussed, other forms of assistive technology 
such as environmental control units (ECU) should be considered. Environmental control 
systems offer sophisticated electronics to enable people with a range of impairments and 
severe disability to use a wide variety of electrical devices. Aids may include unobtrusive 
control units (eg. remote control for TV), home security (door intercoms, door release and 
alarms), adapted telephones (such as hands-free control) and lighting and heating/cooling 
systems (Wellings and Unsworth, 1997). These environmental control units may be used to 
facilitate function and decrease reliance on carers, improve family dynamics and improve 
patients’ self-esteem (Wellings and Unsworth, 1997). It is important for patients, families 
and therapists to work closely together when prescribing and using assistive technology to 
ensure the correct, safe and optimal use of such aids and equipment; and to anticipate future 
needs especially with the expense of such technology. Close collaboration with specialised 
providers of assistive technology that can provide back-up technical support is also crucial. 
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2.6 Bladder, bowel and sexuality 
Although bowel and bladder sphincters are generally spared, bowel, bladder and sexual 
dysfunction may be much more common (30%) than reported to health professionals by 
persons with ALS (Ng et al., 2011). These areas are in general poorly studied in ALS. 
Constipation is common with inactivity and poor nutritional intake, and can be treated with 
a regular bowel program with intake of fibre/bulking agents and adequate fluids. 
Suppositories, stool softeners and enemas should be considered. In one of the few studies 
addressing bladder function in ALS (n=38), 47% had micturition symptoms and 
urodynamics studies found a range of UMN abnormalities (Hattori et al., 1983). Where 
urinary urgency is an issue, oxybutinin may be helpful. Contributory factors to 
incontinence, such as urinary tract infections, drinking large amount of fluids late in the day 
and dependent oedema causing nocturia when the legs are elevated overnight should be 
considered and treated. Wasner et al (Wasner et al., 2004) suggested a prevalence of 62% 
(n=62) in sexual dysfunction with issues including decreased libido and passivity of the 
patient and partner due to physical weakness and the body image changes. The wide 
variation in reported prevalence in bowel, bladder and sexual dysfunction suggests that 
patients may not volunteer this information; hence its inclusion in routine enquiries might 
help to encourage reporting and thus the facilitation of appropriate treatment, such as 
sexual counselling and suggestion of specific techniques. 
2.7 Pain 
Pain is common in ALS (50% in a recent study (Ng et al., 2011)), especially in the later stages. 
Fatigue and depressive symptoms may also worsen a patient’s experience of pain. 
Spasticity and muscle spasms are not an uncommon source of pain and with the current 
paucity of supporting evidence, this is often treated with stretching exercises in combination 
with a muscle relaxant (baclofen is the drug of choice) (Ashworth et al., 2006). Baclofen 
should be started at low doses (5mg twice to three times daily) and slowly increased (up to 
100mg a day in divided doses). Baclofen however can be associated with muscle weakness. 
Tizanidine (2mg twice daily up to 24 mg a day) is likely as efficacious but it is associated 
with dry mouth. Other options include clonidine (25 µg twice a day) which can cause 
hypotension, drowsiness and bradycardia and benzodiazepines which can cause sedation 
and habituation and respiratory depression. Dantrolene is not recommended as it can cause 
excessive muscle weakness in ALS (Krivickas and Carter, 2005). Intrathecal baclofen is 
rarely required but may be indicated in those with intractable spasticity, needing more than 
the maximum oral dose (Marquardt and Seifert, 2002). There are few reports of use of 
botulinum toxin for spasticity in ALS in literature. Caution is advised as persons with ALS 
may be more prone to developing generalised weakness after being injected with botulinum 
toxin A to treat spasticity (Mezaki et al., 1996). 
Muscle cramps can cause severe pain and discomfort and are a result of spontaneous 
activity of motor units induced by contraction of shortened muscles (Norris et al., 1957). The 
list of potentially useful drugs for cramps is extensive, implying efficacy of individual 
agents is low and variable and the evidence base weak. In the US, quinine (35%), baclofen 
(19%), phenytoin (10%), and gabapentin (7%) were the preferred agents (Forshew and 
Bromberg, 2003); in Europe, choices were quinine (58%), benzodiazepines (40%), 
magnesium (25%) and carbamazepine (23%) (Borasio et al., 2001a). In 2006 however, the US 
Food and Drug administration restricted the use of quinine sulfate in the US to treatment of 
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malaria falciparum because of concerns regarding severe adverse events, including 
cardioarthymias, thrombocytopaenia, severe hypersentivity reactions and serious drug 
interaction (U.S. Food and Drug Administration, 2006). 
In advanced disease, pain often results due to immobility. Musculoskeletal pain from 
weakness and resulting postural changes can be ameliorated with range of motion exercises, 
adequate support in sitting and supine positions and proper lifting and transfer techniques 
to prevent undue traction on weakened joints. Equipment such as motorised beds that 
slowly rotate from the side to side can be useful for reducing caregiver burden (Francis et 
al., 1999). Analgesia such as nonsteroidal anti-inflammatory drugs or narcotics (oral or 
sublingual) may also be required (with careful respiratory status monitoring in the latter). 
Intramuscular delivery of medications should be avoided due to muscle wasting (Mayadev 
et al., 2008). 
2.8 Fatigue and sleep disorders  
Fatigue is a common disability in ALS – 77-83% in recent studies (Ng et al., 2011;Ramirez et 
al., 2008) but understudied and often overlooked by clinicians (Lou, 2008). It is unrelated to 
clinical strength as a large component of fatigue in ALS has a central origin (Kent-Braun and 
Miller, 2000). Fatigue in ALS does not correlate directly with gender, educational level, 
disease duration, physical function, quality of life, dyspnoea, depression or sleepiness 
(Ramirez et al., 2008). However, contributory factors may include sepsis (including 
aspiration), depression and/or anxiety, pain, hypoventilation, positioning, sleep disruption 
and effortful activity and these should be treated where possible. It may manifest as reduced 
energy, difficulty in maintaining sustained attention and increased motor weakness, 
incoordination and gait difficulties. No double-blind, placebo-controlled trials have been 
performed for treatment of fatigue. Physostigmine is sometimes prescribed but not 
necessarily effective (Norris et al., 1993). Modafinil appears to be well-tolerated in a recent 
small open-label study (n=15) and may reduce symptoms of fatigue (Carter et al., 2005). 
Rehabilitation strategies involve pacing activities (regular rest breaks), energy conservation 
and fatigue management strategies, addressing sleep disorders, consideration of exercise to 
improve fitness if appropriate and treating other exacerbating factors. 
High incidence of sleep disturbance in ALS has been reported with pain, micturition, and 
choking listed by patients as the most common causes for awakening (Kinnear et al., 1997 
Nov 3-5). Other contributors to poor sleep include abnormal nocturnal movements such as 
periodic leg movements or fragmentary myoclonus, which was demonstrated on 
polysomnography in almost all patients with fatigue (Kinnear et al., 1997 Nov 3-5). Such 
movements may be treated with controlled release carbidopa-levodopa (Sinemet CR) (Sufit, 
1997). Antihistamines (eg. diphenhydramine) and other sedatives (eg. Chloral hydrate 250-
500mg, benzodiazepines) can also be considered once respiratory causes for sleep 
disturbance have been ruled out.  
2.9 Cognition and behavioural impairment 
Cognitive impairment is increasingly recognised in ALS -- 50% are thought to have frontal 
executive deficits (see Table 2) (Lomen-Hoerth et al., 2003). Visuospatial function, praxis and 
memory storage are usually spared (Massman et al., 1996;Abrahams et al., 2005;Ringholz et 
al., 2005). Use of memory aids such as diaries, planners and structured daily routine is 
encouraged. Other conditions (depression, anxiety, fatigue) and medications 
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(anticholinergics, benzodiazepines) should be monitored as they can worsen cognitive 
function. 
Behavioural changes unrelated to mood or cognition has also been noted although estimates 
of prevalence vary widely (Woolley and Jonathan, 2008). Marked apathy occurs in an 
estimated 55% of persons with ALS (Grossman et al., 2007).This correlates with deficits in 
verbal fluency but not depression, disease duration, FVC or ALSFRS scores and may be 
related to fatigue, respiratory weakness, impaired sleep, anxiety or medication (Woolley and 
Jonathan, 2008). It may also be a psychological coping mechanism (Woolley and Jonathan, 
2008). 
In a subset of persons with ALS (approximately 5%), clear fronto-temporal dementia (also 
known as fronto-temporal lobar degeneration) is the presenting picture with severe 
behavioural dysfunction (insidious onset with gradual progression, altered social conduct, 
impaired regulation of personal conduct, emotional blunting, loss of insight) that begins 
before motor weakness becomes obvious (Woolley and Jonathan, 2008). In addition, those 
with fronto-temporal dementia may exhibit disinhibition, restlessness, reduced empathy, 
lack of foresight, impulsiveness, social withdrawal, verbal stereotypes, verbal or motor 
perseveration and/or sexual hyperactivity (Neary et al., 1998). 
Management of behavioural and cognitive deficits can be challenging and begins with the 
identification of these issues. An assessment by a neuropsychologist is often helpful in terms 
of defining the deficits and provision of cognitive and behavioural remediation strategies. 
Education and counselling of the patient and family is important. No trials have been 
conducted in efficacy of pharmacological interventions in this area; however the use of 
antidepressants and antipsychotics may be considered. 
 
Attention and concentration 
Working memory 
Cognitive flexibility (rigidity) 
Response inhibition 
“Executive function” - Planning/problem/solving/abstract reasoning 
Visual-perceptual skills 
Memory 
Word generation (fluency) 
Table 2 Cognitive deficits in ALS (adapted from (Woolley and Jonathan, 2008)) 
2.10 Pseudobulbar affect 
Pseudobulbar affect describes sudden uncontrollable outbursts of laughter or tearfulness 
and is a result of bilateral corticobulbar tract degeneration (Rosen and Cummings, 2007). It 
is common, affecting between 50-70% of persons with ALS (Palmieri et al., 2009) especially 
those with the bulbar form of ALS. Pseudobulbar affect can have a significant impact on 
anxiety and emotional frailty (Palmieri et al., 2009), social functioning and relationships in 
persons with ALS as these sudden, frequent, extreme, uncontrollable emotional outbursts 
may lead to severe embarrassment and social withdrawal (Moore et al., 1997). 
Despite the prevalence of this issue, less than 15% ask for treatment (Meininger, 2005). 
Education of the persons with ALS and their family and friends assists with understanding 
and acceptance of these pathological and involuntary outbursts and is an important 
component of the appropriate treatment of pseudobulbar affect. Crying associated with 
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pseudobulbar affect is easily incorrectly interpreted as depression; laughter may be 
embarrassing. Pharmacological treatment can include amitryiptiline (10-150mg nocte, 
starting with 10mg and slowly increasing the dose) which also has the positive benefit on 
weight loss and loss of appetite (Meininger, 2005) or fluvoxamine (100-200mg daily). A more 
recent study (n=140) showed that dextromethorphan and quinidine in combination appears 
to be more effective in reducing the frequency and severity of psudobulbar affect and to 
improve quality of life) (Brooks et al., 2004). However, side effects are also more common 
(nausea, dizziness, gastrointestinal complaints) (Brooks et al., 2004). 
2.11 Psychosocial issues 
ALS is a devastating condition, which takes its toll on the patient and family especially as 
the disease progresses, and loss of independence occurs. Rates of depression and anxiety are 
reported to be 0-44% and 0-30% respectively in persons with ALS (Kurt et al., 2007) and 
depression does not appear to increase in more advanced disease (Rabkin et al., 2005). 
Quality of life also appears to be more dependent on psychological and existential factors 
than physical factors (Goldstein et al., 2006b;Simmons et al., 2000). Amongst caregivers, 23% 
are depressed (Rabkin et al., 2009) and caregiver strain is often significant as a result of 
increased caregiving time, cognitive impairments in persons with ALS, emotional labour 
and socio-economic considerations (Chio et al., 2006;Goldstein et al., 2006a;Ray and Street, 
2006). Hence, referrals to support groups and counselling and education of patients and 
their families (often their caregivers) are essential. Frank discussions facilitate 
understanding of the disease and improve coping skills. Carer support (both physical and 
emotional) and respite care should be discussed. Referrals to the local ALS associations are 
also recommended as these provide patients and families with ongoing support, resources 
and equipment needs. Psychotherapy should also be considered to assist with coping 
strategies (Matuz et al., 2010). Antidepressants such as amitriptyline and selective serotonin 
reuptake inhibitors may be used, the former being also useful for other symptoms such as 
drooling, pseudobulbar affect and insomnia. Anxiety is difficult to measure due to physical 
confounding symptoms such as shortness of breath, muscle cramps and restlessness. 
Anxiety can be treated with psychotherapy and training in relaxation and breathing 
techniques, as well as participation in support groups. It is generally thought that the rates 
of anxiety increase in the pre-terminal stage (Kurt et al., 2007), hence anxiolytics at this time 
such as benzodiazepines should be offered. With good support, mental health and quality of 
life can remain stable despite deteriorating physical health (De Groot et al., 2007). 
2.12 End of life issues 
It is important to establish an open environment of communication with persons with ALS 
and their families from the time of diagnosis. Specialist palliative care providers should be 
involved as early as possible. Discussions should take place early, well before specific 
decisions need to be made. The actual timing of when to introduce these discussions 
however can be challenging and will depend on a number of factors including coping skills, 
depression and anxiety, cultural issues and functional status (Mitsumoto et al., 2005). Some 
triggers may include the patient or family initiation of discussion, severe psychosocial 
distress, pain requiring high dosages of analgesia, dysphagia, dyspnoea and functional loss 
in two body regions (Mitsumoto et al., 2005). Given the progressive nature of the disease, 
the patient eventually has to choose between life-sustaining therapies (respiratory 
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assistance, feeding tubes) and terminal palliative care whilst considering issues relating to 
quality of life, burden of therapies, their own wishes and those of their family. It is 
important that clinicians caring for ALS patients and their families appreciate and 
communicate the significance of life-threatening symptoms, monitor decision-making 
capacity, ensure that multiple possible end of life scenarios are anticipated and managed 
with all options provided (including hospice care), review advance care directives and 
comprehensively consider and aggressively manage symptoms (McCluskey, 2007). 
Medications should be available for all patients who are deteriorating and may be 
approaching the terminal phase, although the terminal phase may be difficult to recognise 
as there is usually slow deterioration until a quicker change leads to death within a few days 
or less (Oliver, 2007). Medications should include morphine to relieve dyspnoea and pain, 
midazolam to relieve distress and agitation and glycopyrronium bromide or hyoscine 
hydrobromide to reduce chest secretions, delivered parenterally (Oliver, 2007). Cultural and 
spiritual issues should also be addressed (Mitsumoto et al., 2005;Albert et al., 2007). 
Although many persons with ALS fear the terminal stages of ALS, with good palliative care, 
the later stages can be a time of fulfilment and peace for both persons with ALS and their 
families (Oliver, 2007). 
Bereavement in ALS occurs in both the patient and their family and continues, in families, 
after the death of the patient. Some families feel relieved of their caregiver burden and the 
burden of losses for the patient but also have feelings of guilt that they feel these emotions; 
hence support is vital in this area (Skyes, 2006). 
3. Conclusion 
ALS is a complex and challenging condition with no cure. Current “gold-standard” 
management is ‘‘multidisciplinary care’‘which includes neurological, rehabilitative and 
palliative care.  As consistent with the guidelines from the American Academy of Neurology 
(Miller et al., 2009b) and the World Federation of Neurology (Andersen et al., 2007), 
multidisciplinary care should be available to all persons with ALS. Where multidisciplinary 
care is currently available, it should be delivered with a high level of coordination and 
integration, with evidence-based intervention to ensure holistic and seamless care for persons 
with ALS and their caregivers. Many areas in ALS are poorly understood, with research often 
further hindered by the logistical and ethical difficulties. Much more work is needed in the area 
of evidence-based interventions. At present, much of the evidence has been concentrated in 
areas such as respiratory and nutritional management.  There is paucity of information on 
effective rehabilitation interventions and very little is understood with regards to the “black box 
of rehabilitation”.  For example, evidence to guide exercise prescription (such as strengthening, 
stretching, aerobic/endurance exercises) is much needed.  The use and development of assistive 
technology is another area that warrants much more attention, as is a better understanding of 
bowel, bladder and sexuality issues. Further research is also needed into appropriate study 
designs; outcome measurement; the evaluation of optimal settings, type, intensity or frequency 
and cost-effectiveness of multidisciplinary care; and the different phases of ALS, covering the 
spectrum of care required for this patient population. The interface between neurological, 
rehabilitative and palliative components of care, and caregiver needs should be explored and 
developed to provide long-term support for this population.  Last but not least, national and 
international guidelines incorporating evidence-based practice in rehabilitation should be 
further developed to enable optimisation of clinical care and practice. 
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